EP-1075: Acute anorectal and urinary toxicities in prostate cancer patients treated with IMRT and 3D-CRT

T. Akiba, E. Kunieda, R. Nagao, T. Fukuzawa, A. Kogawa, T. Komatsu, Y. Tamai, Y. Oizumi
2013 Radiotherapy and Oncology  
2nd ESTRO Forum 2013 S405 Perineural invasion pre-RP: Yes, 11 (6.92%); No, 108 (67.92%) and unknown, 40 (25.16%). Post-RP PSA: < 0.20 ng/ml: 88 (55.34%), ≥ 0.20 ng/ml (Permanently Detectable-PSA or PD-PSA): 55 (34.59%) and unknown: 16 (10.06%). Initial EBRT intention: Adjuvant: 46 (28.93%), Salvage: 113 (71.07%). Corrected EBRT intention: Adjuvant: 23 (14.46%), Salvage: 136 (85.53%), with 23 patients with a PD-PSA (Post-RP PSA > 0.20 ng/ml). Androgenic deprivation: Yes 47 (29.56%), No: 112
more » ... .56%), No: 112 (70.44%). Time from BF diagnosis to EBRT referral: Mean: 16.95 months (m), median: 5.50 m, range [0-147 m]. Pre-EBRT PSA: <1 ng/ml: 84 (52.83%), ≥1 ng/ml: 56 (35.22%), unknown: 19 (11.95%). EBRT Dose: 66 Gy: 24 (19.74%), 70 Gy: 79 (59,21%), 72-74 Gy: 45 (21,05%), interrupted: 1 (0,63%) . After a median-FU of 23 m, 101 patients (63.52%) remains free of biochemical progression, 16 patients (10.06%) have BP and 42 (26.42%) are lost. Perineural invasion pre-RP is a predictor of poor prognosis after post-RP EBRT (p = 0.012). There is a statistically significant benefit in BFFS when RT dose is >72 Gy (p = 0.048), moreover when patients with PD-PSA are analyzed (p = 0.010). The beneficial effect of increased dose is maintained when pre-EBRT PSA is <1 ng/ml (p = 0.008), but not when pre-EBRT PSA is > 1 ng/ml (p = 0.139). Conclusions: The majority of patients remitted to our Service for EBRT treatment, followed the criteria established for salvagetreatment. Perineural invasion before RT appeared as a bad prognosis factor. Doses over 72 Gy were associated to longer times to BFFS, especially in those patients with PD-PSA. This effect was observed even when PSE pre.EBRT is < 1 ng/ml, but was not observed when that value was > 1 ng/ml. EP-1073 Initial experience with extreme hypofractionation (5.65 Gy x 8 in 3 weeks) in localised prostate cancer
doi:10.1016/s0167-8140(15)33381-8 fatcat:kiqjqbi7pvb7zdoy2dtbb23jba